Edunn Biotechnology

Edunn Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation 'off-the-shelf' cell therapies using induced pluripotent stem cell (iPSC) technology. The company specializes in the differentiation of iPSCs into various immune cells, including Natural Killer (NK) cells and T cells, to treat cancers and autoimmune disorders. By leveraging its proprietary platform, Edunn aims to overcome the limitations of traditional autologous CAR-T therapies, such as high costs and complex manufacturing processes. Their pipeline includes several candidates targeting hematological malignancies and solid tumors, as well as applications in regenerative medicine.